No specific treatments are currently available for triple negative breast cancer (TNBC), a type of tumour that lacks the receptors targeted by many breast cancer therapies.
Although many TNBC tumours lack two tumour suppressors, RB1 and p53, the specific downstream pathways that can be targeted as potential treatments for these tumours have not been identified.
In this issue of the JCI, a team led by Eldad Zacksenhaus at Toronto General Research Institute discovered that the growth of TNBC-like breast tumours is supported by enhanced mitochondrial function.
Mice carrying tumours that were deficient in both RB1 and p53 displayed upregulation of a pathway that controls the synthesis of mitochondrial proteins.
They then identified an FDA-approved drug, tigecycline, that blocks this upregulation and reduces the growth of TNBC-like tumours in mice.
This work suggests that inhibiting mitochondrial protein translation could potentially be a successful treatment for TNBC.
Source: JCI
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.